Progress against HIV, malaria and TB is under threat, putting children at risk. Here’s what is needed.
COVID-19 and drug resistance are threatening to derail the progress made against the HIV, malaria and TB epidemics. With the last mile in sight, greater momentum is needed to develop new child-friendly medicines for these diseases and to rapidly make them widely accessible. This new series of articles from the Access to Medicine Foundation assesses the current situation for each of the three diseases and how to end their burden on children.
As the COVID-19 pandemic deepens, it disrupts health systems bringing prevention and treatments programmes to a halt. These disruptions are predicted to lead to a spike in deaths from HIV, malaria and TB. Models predict twice as many deaths from malaria in sub-Saharan Africa in 2020 as in 2018; an additional 1.4 million TB deaths over the next five years globally; and significant increases in new HIV infections in children, ranging from 37% in Mozambique to 104% in Uganda. The pandemic also risks accelerating the rate at which drug resistance is emerging.
Last mile in sight
HIV, malaria and TB pose the greatest risk to children, especially those living in low- and middle-income countries. Termed the ‘big three' for their combined impact on human health, these infectious diseases have long been the target of international collaboration and funding. As a result, mother-to-child transmission of HIV has decreased by almost half in East and Southern Africa since 2010, and malaria deaths have dropped by approximately 30% since 2010. Nevertheless, they still account for over half a million child deaths each year, mostly in children under the age of five.
“After decades of investment, the last mile is in sight. To continue the fight against these diseases, while also battling COVID-19 and drug resistance, children urgently need child-sized medicines. Yet they are waiting last in line for life-saving treatments," says Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation. "These timelines can be shortened with an ‘all hands-on deck’ response involving the pharmaceutical industry, regulators, governments, NGOs and civil society.”
Birds-eye view of pharma engagement
The Access to Medicine Foundation has now published a birds-eye view of pharmaceutical industry engagement with this issue. Its new series of articles maps current paediatric pipelines and product gaps for children with HIV, malaria and TB, underscoring the impact that these diseases have on children and highlighting the challenges that threaten progress. The articles identify nine case studies of real action from pharmaceutical companies and organisations working towards the delivery of these much-needed paediatric treatments.
New analysis of the challenges
The three articles each dive into the current situation for one of the three diseases, setting out which new child-friendly treatments are needed and specific actions for ensuring their availability.
HIV: drug resistance increases need for new child-friendly treatments
The article on HIV covers how the number of new paediatric HIV infections has decreased significantly in recent years. While this is an extremely positive trend, it also means that the market for child-friendly ARVs is shrinking, making it less attractive for pharmaceutical companies to invest in developing new ones. With one in two newly diagnosed children showing resistance to commonly used ARVs, new treatments that are child-friendly are needed to replace those that are no longer effective.
Malaria: High-quality child-friendly antimalarials are needed
The article on malaria highlights how, although children under five are most vulnerable to malaria, the availability of child-friendly antimalarials is limited. In the meantime, suboptimal treatments or even substandard and falsified antimalarials medicines are prevalent, which increases the threat of drug resistance. The development and delivery of high-quality, optimal formulations for children are urgently required.
TB: New incentives and priorities are needed to direct focus on MDR-TB
In the article on TB, adherence issues are highlighted as a particular challenge for children with multidrug-resistant TB (MDR-TB), as treatment regimens can be long and gruelling. Yet poor adherence also drives drug resistance. Sustained collaborative action between public and private actors will be essential to ensure access to much-needed MDR-TB medicines for children.
While each of the three epidemics pose unique challenges, common areas of action have been identified as a basis for scaling up progress. The series of articles published today makes clear that this a shared responsibility between the pharmaceutical industry, regulators and governments.
“We must always put vulnerable populations front and centre in our global response to infectious diseases – this includes children living in low- and middle-income countries. That’s how we will finish the fight against such diseases, whether new threats such as COVID19, or endemic ones such as HIV, malaria and TB,” says Iyer.
About the Access to Medicine Foundation
The Access to Medicine Foundation is an independent non-profit organisation based in the Netherlands, which analyses how the world's largest pharmaceutical companies are addressing access to medicine. Its mission is to stimulate and guide pharmaceutical companies to do more for the people who live in low- and middle-income countries. The Foundation defines the actions pharmaceutical companies can and should be taking through a process of stakeholder consensus building, gathering the views of independent experts in global health, access to medicine and the industry. The Foundation is funded by UK Aid, the Dutch Ministry of Foreign Affairs, the Bill & Melinda Gates Foundation and the Dutch Ministry of Health, Welfare and Sport.
Ending the burden of HIV, malaria and TB in children
This series of articles stress the urgent need for new “child-friendly” treatments for HIV, malaria and TB to end the burden these diseases have on children, especially with the looming impact of COVID-19 and emerging drug resistance.
“I welcome this comprehensive article on ending the burden of HIV, malaria and TB in children, and especially appreciate the strong emphasis on the crying need for children living with HIV to access the most up-to-date paediatric ARVs.”
Sister Mary Owens
Executive Director of COGRI - Nyumbani programs for children living with HIV
"I support the Access to Medicine Foundation's work to draw attention to the pressing issue of paediatric drug resistance and specifically pertaining to HIV, malaria and TB, along with their work to incentivise pharmaceutical companies to do more for children living in low-and-middle-income countries. Going forward, the need for new vaccines and treatments for children to address ongoing epidemics must not be forgotten.''
Professor Mike Sharland
Consultant in Paediatric Infectious Diseases at St George's University Hospitals NHS Foundation Trust
"No child should die of TB. That is why we’re working with our partners to expand the pediatric R&D pipeline. We welcome this new report for highlighting the progress to date and raising awareness of the work that still needs to be done to advance the development and delivery of new child-friendly MDR-TB treatments.”
President and CEO, TB Alliance
"While COVID19 is dominating health systems globally, many children are still on the frontlines of the ‘big three’ infectious diseases — HIV, malaria and TB — all of which still require urgent vaccine development to save lives. The Access to Medicine Foundation provides important research and analysis on key paediatric access and drug resistance issues and incentivises companies to take action.''
Ambassador for Women's Rights and Gender Equality, Dutch Ministry of Foreign Affairs